View More Recent Stories
-
7 top biotech picks for 2025 according to Wells Fargo
-
Biotech outlook for 2025: Stifel
-
Stifel Highlights Iovanace Biotherapeutics (IOVA) as 'Top Pick' in Biotech's 2025 Outlook Note
-
Iovance Biotherapeutics (IOVA) Promotes Raj Puri to Chief Regulatory Officer
-
Iovance Biotherapeutics (IOVA) Tops Q3 EPS by 2c
-
UBS Starts Iovanace Biotherapeutics (IOVA) at Buy
-
Baird Reiterates Outperform Rating on Iovanace Biotherapeutics (IOVA)
-
TD Cowen Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird
-
Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral
-
H.C. Wainwright Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Iovance Biotherapeutics (IOVA) Submits Marketing Authorization Application to EMA for Lifileucel
-
Iovance Biotherapeutics (IOVA) Submits MAA to EMA for Lifileucel in Advanced Melanoma

